[EN] SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF<br/>[FR] SELS D'OUVREURS DES CANAUX POTASSIQUES ATP ET LEURS UTILISATIONS
申请人:ESSENTIALIS INC
公开号:WO2013130411A1
公开(公告)日:2013-09-06
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
申请人:Cowen Neil M.
公开号:US20120238554A1
公开(公告)日:2012-09-20
Provided are immediate or prolonged administration of certain salts of K
ATP
channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K
ATP
channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
Salts of potassium ATP channel openers and uses thereof
申请人:Essentialis, Inc.
公开号:EP2404604A1
公开(公告)日:2012-01-11
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.